Investor Relations Home

Profile
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.
Stock Quote
IRIX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.50
Change (%) Stock is Up 0.12 (2.74%)
Volume14,023
Data as of 02/15/19 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
02/12/19IRIDEX Announces Resolution of its Dispute with Quantel Medical
MOUNTAIN VIEW, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has resolved its differences with Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. (collectively, “Quantel”) in its lawsuit filed against Quantel in the U.S. District Court for the Northern District of California. IRIDEX dismissed the lawsuit it had filed in January 2018, alleging that Quantel products infringed IRIDEX’s U.S. Patent No. 7,771,417, that Quantel breached ... 
Printer Friendly Version
01/08/19IRIDEX Announces Preliminary Operational and Financial Results for 2018 Fourth Quarter and Full Year
MOUNTAIN VIEW, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 29, 2018. Highlights Shipped approximately 460 to 465 Cyclo G6® Glaucoma Laser Systems and 45,500 to 46,500 G6 probes in the full year 2018 Shipped approximately 119 to 124 Cyclo G6® Glaucoma Laser Systems and a record 12,000 to 13,000 G6 probes in the fourth quarter 2018 Total r... 
Printer Friendly Version
12/04/18IRIDEX Announces Departure of Chief Financial Officer and Reiterates Full Year 2018 Guidance
MOUNTAIN VIEW, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced Chief Financial Officer Atabak Mokari will leave the Company for a senior finance executive role at another company. Mokari has agreed to assist in the orderly transition of his CFO responsibilities and will leave the Company effective December 18, 2018. IRIDEX plans to search for a replacement. “We would like to thank Atabak for his service throughout the significant transformation of... 
Printer Friendly Version
11/01/18IRIDEX Announces 2018 Third Quarter Financial Results and Raises Full Year 2018 Guidance
MOUNTAIN VIEW, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 29, 2018. Third Quarter Highlights Cyclo G6™ product revenue increased approximately 23% year-over-year Shipped 10,400 G6 probes Shipped 117 G6 laser systems Total revenue of $11.3 million Received FDA Clearance to introduce updated TruFocus LIO Premiere™ Laser Accessory to the U.S. Market Compl... 
Printer Friendly Version
Primary IR Contact
Lynn Lewis or Leigh Salvo
Phone: (415) 937-5404
E-mail: investors@iridex.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


logo aa0logo agslogo ascrslogo asrslogo esrs0logo euretina